Collaborative practice agreement adoption authorized. A school administrative unit or an approved private school may authorize adoption of a collaborative practice agreement for the purposes of stocking and administering epinephrine autoinjectors as provided under this section. The administration of an epinephrine autoinjector in accordance with this section is not the practice of medicine. [PL 2013, c. 526, §1 (NEW).]
Collaborative practice agreement terms and provisions. A collaborative practice agreement must include the following information:
A. Name and physical address of the school; [PL 2013, c. 526, §1 (NEW).]
B. Identification and signatures of the physician or school health advisor under section 6402‑A and school nurse under section 6403‑A who are parties to the collaborative practice agreement, the dates the agreement is signed by each party and the beginning and end dates of the period of time within which the agreement is in effect; and [PL 2013, c. 526, §1 (NEW).]
C. Any other information considered appropriate by the physician or school health advisor under section 6402‑A and school nurse under section 6403‑A. [PL 2013, c. 526, §1 (NEW).] [PL 2013, c. 526, §1 (NEW).]
Collaborative practice agreement. Under this collaborative practice agreement, UConn Health Anticoagulation Specialist(s), according to and in compliance with section 91 of Public Act 10-117 and Connecticut General Statues sec 20-631 “Collaborative Drug Therapy Management”, may design, implement, and monitor a therapeutic drug plan intended to manage anticoagulation therapies. Anticoagulation Specialists may sign patient summaries for assisted living facilities as well as orders for visiting nurses. Services offered by the Anticoagulation Specialist may include education on disease state and lifestyle modification, in addition to the drug therapy services listed above. Written educational materials and patient specific information may be provided to improve quality of care. The Anticoagulation Specialist(s) may initiate, discontinue, or adjust anticoagulation therapies in accordance with current treatment guidelines, may order laboratory tests appropriate to the disease or drug therapy. Education at office visits shall include appropriate counseling on all new medications. The results of all lab tests ordered under the protocol shall be reviewed and managed by the Anticoagulation Specialist(s) to assess efficacy of treatment and necessity for medication and/or therapeutic lifestyle change. Lab results will be relayed to clinic patients by a patient-specific predetermined method which may include face-to-face encounter, written communication, secure electronic, or telephone communication. Any lab outliers that require further investigation will be sent to the referring physician and/or PCP as appropriate and the patient will be told to contact that LIP immediately. If the LIP is not available, the patient will be sent to the UConn Health Emergency Department. A patient whose drug therapy is managed under this agreement must have established care with a provider within UConn Health and all aspects of the patient’s anticoagulation medication management will be followed in collaboration with the patient’s referring provider (or primary care as necessary). In addition, the patient must be seen by their UConn Health provider at least once per year, in addition to which cases may be reviewed with clinic medical directors as needed. All issues outside of the scope of anticoagulation medication management shall be referred to the patient’s primary care provider, daily supervising LIP or medical director(s). The Anticoagulation Specialist(s) will assure documentation of allergies and adverse drug re...
Collaborative practice agreement adoption authorized. A school administrative unit or an approved private school may authorize adoption of a collaborative practice agreement for the purposes of stocking, possessing and administering naloxone hydrochloride as provided under this section. The administration of naloxone hydrochloride in accordance with this section is not the practice of medicine. [PL 2021, c. 115, §1 (NEW).]
Collaborative practice agreement terms and provisions. A collaborative practice agreement must include the following information:
A. Name and address of the school; [PL 2021, c. 115, §1 (NEW).]
B. Identification and signatures of the physician or school health advisor and school nurse who are parties to the collaborative practice agreement, the dates the agreement is signed by each party and the beginning and end dates of the period of time within which the agreement is in effect; and [PL 2021, c. 115, §1 (NEW).]
C. Any other information considered appropriate by the physician or school health advisor and school nurse. [PL 2021, c. 115, §1 (NEW).] [PL 2021, c. 115, §1 (NEW).]
Collaborative practice agreement. NOTICE OF INTENT advanced practice registered nurse by the. Requirements for Provider Type 09 Certified Registered. NYS Nursing Practice
Collaborative practice agreement. SSM Physician
a. Description: Agreement between an SSM employed physician and an Advanced Practice Registered Nurse (APRN) that is required for an APRN to maintain privileges for prescribing medication and performing other advanced medical tasks.
Collaborative practice agreement. This collaborative practice agreement is an expanded scope of practice of the pharmacist identified herein. Upon approval of this agreement by the IWK Medical Advisory Committee, the Nova Scotia College of Pharmacists will approve the practice setting prior to the Collaborative Practice Agreement taking effect under section 3f of the Pharmacy Practice Regulations.
Collaborative practice agreement. Under this collaborative practice agreement, UConn Health – Xxxx Xxxxxxx Hospital (UCH/JDH) Pharmacists, according to and in compliance with Section 91 of Public Act 10-7 and Connecticut General Statutes sec 20-631 “An Act Concerning Collaborative Practice Between Physicians and Pharmacists”, may design, implement, and monitor a therapeutic drug plan intended to manage IV Aminoglycoside therapy upon receipt of an order from the licensed provider to the Pharmacist for IV Aminoglycoside dosing. The specific services provided by the Pharmacists and the methods for providing these services are described in detail in this protocol document
Collaborative practice agreement. Under this collaborative practice agreement, UConn Health – Xxxx Xxxxxxx Hospital Pharmacists, according to and in compliance with Section 91 of Public Act 10-7 and Connecticut General Statutes sec 20-631 “An Act Concerning Collaborative Practice Between Physicians and Pharmacists”, may design, implement, and monitor a therapeutic drug plan intended to manage IV Vancomycin therapy upon receipt of an order from the licensed provider to the Pharmacist for IV Vancomycin dosing. The specific services provided by the Pharmacists and the methods for providing these services are described in detail in this protocol document
